Related Experiment Video

Updated: Apr 18, 2026

Th17 Inflammation Model of Oropharyngeal Candidiasis in Immunodeficient Mice
08:02

Th17 Inflammation Model of Oropharyngeal Candidiasis in Immunodeficient Mice

Published on: February 18, 2015

10.5K

Mycosis Fungoides Following IL-17 Inhibitor Treatment: A Case Series of Five Patients

Shan Zhang1, Zhiyu Pang1, Jie Liu1

  • 1Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

The Journal of Dermatology
|April 17, 2026
PubMed

Insights

Interleukin-17 (IL-17) inhibitors, used for psoriasis, may accelerate mycosis fungoides (MF) progression. Consider MF in patients with atypical psoriasis unresponsive to biologics; skin biopsy is crucial for diagnosis.

Area of Science:

  • Dermatology
  • Immunology
  • Oncology

Background:

  • Interleukin-17 (IL-17) inhibitors are effective biologic treatments for moderate-to-severe plaque psoriasis.
  • Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma.

Purpose of the Study:

  • To report cases of mycosis fungoides (MF) initially treated with IL-17 inhibitors for psoriasis.
  • To hypothesize the potential role of IL-17 inhibitors in promoting MF progression.

Main Methods:

  • Case series analysis of five patients with psoriasis treated with IL-17 inhibitors.
  • Clinical feature summarization and hypothesis formulation regarding immune response disruption.

Main Results:

  • Five patients initially treated for psoriasis with IL-17 inhibitors showed disease progression and were diagnosed with mycosis fungoides (MF).
  • Hypothesized mechanisms include impaired anti-tumor immunity and disrupted Treg/Th17 balance.

Conclusions:

  • The possibility of MF should be considered in psoriasis patients exhibiting atypical presentations or poor response to biologic therapy.
  • A skin biopsy is recommended for definitive diagnosis, especially before initiating biologic treatment in suspicious cases.
Keywords:
IL‐17 inhibitorbiologicscutaneous T‐cell lymphomamycosis fungoidespsoriasis

More Related Videos

Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples07:43

Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples

Published on: July 29, 2017

10.4K
Detection and Isolation of Viable Mouse IL-17-Secreting T Cells12:38

Detection and Isolation of Viable Mouse IL-17-Secreting T Cells

Published on: December 18, 2008

11.7K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
732
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.5K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
685
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
820